Lumenis Overview
Lumenis provides minimally invasive clinical solutions for the surgical, ophthalmologic, and aesthetic markets, and develops and commercializes energy-based technologies including laser, intense pulsed light, and radio frequency. Lumenis has successfully created solutions for previously untreatable conditions and has designed technologies that have addressed existing treatment methods in every one of the sectors it operates in.
Cumulative Funding Raised Over Time ($)
$510KDec 1992
$2.5MJan 1994
Latest News
growth-positive
Lumenis introduces FoLix™, the first FDA-cleared proprietary fractional laser for hair loss treatment
Lumenis Be. Ltd., a medical device company, has launched FoLix, a laser system designed to combat hair loss. The system, which has been cleared by the FDA, is the first and only fractional laser treatment for hair loss in the US. FoLix uses Lumenis proprietary technology to stimulate hair follicles, offering results in 4-6 monthly sessions without the need for chemicals, needles, anesthesia, surgery, or downtime. The companys studies have shown a positive impact on hair growth, with improvements in scalp hair appearance and an increase in hair count.
Customers
growth-positive
Lumenis' triLift Awarded "Best New Dermatology Technology Solution" in 8th Annual MedTech Breakthrough Awards Program
Lumenis Be Ltd., a leading energy-based medical device company, has announced that its product, triLift, has won the Best New Dermatology Technology Solution award in the 8th annual MedTech Breakthrough Awards program. triLifts facial muscle stimulation treatment is a breakthrough in facial aesthetics, targeting the root cause of facial aging - the muscles. The treatment uses Dynamic Muscle Stimulation technology to stimulate and tone facial muscles, achieving a toned and lifted look. The treatment also addresses the skin and volume through the integration of two more synergistic technologies.
Customers
growth-positive
Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology
Lumenis Be., an energy-based medical device company, announced that its product OptiLight has won the MedTech Breakthrough Award for Best New Technology Solution for Ophthalmology. OptiLight, introduced in May 2021, is the first and only light treatment FDA approved for management of dry eye disease. The company recently launched a national media campaign featuring Mandy Moore to increase awareness for dry eye disease and encourage people to seek out a physician who offers OptiLight.
Customers
growth-positive
Lumenis Disrupts the Energy-Based Treatment Category with a New Facial Stimulation Treatment, triLift™, at the 2022 American Academy of Dermatology (AAD)
Lumenis Be, Ltd. has launched triLift, a facial stimulation device targeting the three aging elements. The device uses Dynamic Muscle Stimulation (DMStTM) along with other modalities to tone muscles, reduce wrinkles, and improve skin texture. Studies have shown that triLift can increase skin smoothness, reduce wrinkles, and triple the production of Hyaluronic Acid. The company aims to provide a noninvasive, no downtime approach to firming the face. Lumenis is a global leader in the medical aesthetic market and is known for developing and commercializing innovative energy-based technologies. The launch of triLift expands their portfolio of aesthetic solutions.
CustomersPartners
growth-positive
Lumenis partners with Mandy Moore on DED awareness
Lumenis has partnered with actress and singer-songwriter Mandy Moore for their dry eye disease treatment, OptiLight. Moore, who experienced symptoms of dry eye disease, found significant improvement with OptiLight treatment. She is now the brand ambassador for the product and will be featured in a campaign. The partnership aims to inspire others to seek treatment for the condition.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $77.51M |
| Last funding | $75M |
| Stage | Acquired |
| Rounds | 4 |
| Investors | 0 |
Team Members
5
Employees: 500+
Web & Social Links
| Website | lumenis.com |
| Careers | Careers page |
Locations
HaKidma Street 6, Yokne'am Illit, Israel
Golf course road, Gurgaon-122002 Haryana , India
2077 Gateway Place, San Jose, CA, United States
1 Guanghua Road, Guomao, Chaoyang, Beijing, China
385 Centennial Avenue, Elstree, Borehamwood, Hertfordshire WD6 3TN, United Kingdom
10 Gukjegeumyung-ro, Yeoeuido-dong, Yeongdeungpo-gu, Seoul, South Korea
Via Giulio Vincenzo Bona, 87, 00156 Roma, Metropolitan City of Rome, Italy
821 Pacific Highway, Chatswood NSW 2067, Australia
Oi, Shinagawa, Tokyo, Japan
Heinrich-Hertz-Strae 3, Dreieichenhain Dreieich, Germany
33 Cameron Road, Tsim Sha Tsui, Hong Kong
Section 1, Keelung Road, Xinyi District, Taipei City, Taiwan
Photos & Videos
3 item(s)
Lumenis Business
Business models
B2B
Product stage
Released
Employees
500+
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
SensingLaserMachinery & RoboticsTags (15)
medical-deviceshospitalssurgerylasersglaucomaclinicsminimally-invasiveeye-diseasesgynecologyskin-careophthalmologyurologypulmonarygastroenterologynon-invasiveGeographic Markets
AustraliaUnited KingdomIndiaChinaTaiwanSouth KoreaUnited StatesGlobalGermanyHong KongJapanItalyLumenis Financials
$77.51M
Total funding
Undisclosed
Capital raised
$75M
Last funding
Acquired
Funding stage
4
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$510KDec 1992
$2.5MJan 1994
Private Equity Funding
Undisclosed Round
Jan 1994
$2M
Seed
Dec 1992
$510K
Public Offering / Exit
MNAEvent
Feb 2020
Undisclosed
DelistingEvent
Oct 2015
Undisclosed
MNAEvent
Jun 2015
$510M
POEvent
Jul 2014
Undisclosed
POEvent
Jan 1996
Undisclosed
Mergers & Acquisitions
MNAEvent
Nov 2015
Undisclosed
Lumenis Lifecycle
Cumulative Funding Raised Over Time
$510KDec 1992
$2.5MJan 1994
All Events
Undisclosed Round
Jan 1994
$2M
Seed
Dec 1992
$510K
MNAEvent
Feb 2020
Undisclosed
DelistingEvent
Oct 2015
Undisclosed
MNAEvent
Jun 2015
$510M
POEvent
Jul 2014
Undisclosed
POEvent
Jan 1996
Undisclosed
MNAEvent
Nov 2015
Undisclosed
Lumenis News
34 articles
growth-positive
Lumenis introduces FoLix™, the first FDA-cleared proprietary fractional laser for hair loss treatment
Lumenis Be. Ltd., a medical device company, has launched FoLix, a laser system designed to combat hair loss. The system, which has been cleared by the FDA, is the first and only fractional laser treatment for hair loss in the US. FoLix uses Lumenis proprietary technology to stimulate hair follicles, offering results in 4-6 monthly sessions without the need for chemicals, needles, anesthesia, surgery, or downtime. The companys studies have shown a positive impact on hair growth, with improvements in scalp hair appearance and an increase in hair count.
Customers
growth-positive
Lumenis' triLift Awarded "Best New Dermatology Technology Solution" in 8th Annual MedTech Breakthrough Awards Program
Lumenis Be Ltd., a leading energy-based medical device company, has announced that its product, triLift, has won the Best New Dermatology Technology Solution award in the 8th annual MedTech Breakthrough Awards program. triLifts facial muscle stimulation treatment is a breakthrough in facial aesthetics, targeting the root cause of facial aging - the muscles. The treatment uses Dynamic Muscle Stimulation technology to stimulate and tone facial muscles, achieving a toned and lifted look. The treatment also addresses the skin and volume through the integration of two more synergistic technologies.
Customers
growth-positive
Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology
Lumenis Be., an energy-based medical device company, announced that its product OptiLight has won the MedTech Breakthrough Award for Best New Technology Solution for Ophthalmology. OptiLight, introduced in May 2021, is the first and only light treatment FDA approved for management of dry eye disease. The company recently launched a national media campaign featuring Mandy Moore to increase awareness for dry eye disease and encourage people to seek out a physician who offers OptiLight.
Customers
growth-positive
Lumenis Disrupts the Energy-Based Treatment Category with a New Facial Stimulation Treatment, triLift™, at the 2022 American Academy of Dermatology (AAD)
Lumenis Be, Ltd. has launched triLift, a facial stimulation device targeting the three aging elements. The device uses Dynamic Muscle Stimulation (DMStTM) along with other modalities to tone muscles, reduce wrinkles, and improve skin texture. Studies have shown that triLift can increase skin smoothness, reduce wrinkles, and triple the production of Hyaluronic Acid. The company aims to provide a noninvasive, no downtime approach to firming the face. Lumenis is a global leader in the medical aesthetic market and is known for developing and commercializing innovative energy-based technologies. The launch of triLift expands their portfolio of aesthetic solutions.
CustomersPartners
growth-positive
Lumenis partners with Mandy Moore on DED awareness
Lumenis has partnered with actress and singer-songwriter Mandy Moore for their dry eye disease treatment, OptiLight. Moore, who experienced symptoms of dry eye disease, found significant improvement with OptiLight treatment. She is now the brand ambassador for the product and will be featured in a campaign. The partnership aims to inspire others to seek treatment for the condition.
Customers
growth-positive
Boston Scientific completes Lumenis surgical $1b acquisition
Boston Scientific has completed the acquisition of Lumenis surgical business for $1.07 billion. Lumenis will retain 1,000 employees in its laser and RF activities and is expanding these activities. Boston Scientific plans to integrate Lumenis laser portfolio with its kidney stone management and benign prostatic hyperplasia offerings, while also expanding its global footprint. The acquisition allows Boston Scientific to establish a global surgical laser center of excellence in Yokneam, Israel. Boston Scientific has had a relationship with Lumenis for over 20 years and currently sells Lumenis urology laser portfolio in the US and Japan through a distribution arrangement.
AcquisitionExpand
growth-positive
Behind the Lumenis makeover
Lumenis, a Yokneam-based medical equipment company, has seen significant growth in value under the leadership of CEO Tzipi Ozer-Armon. The company recently signed a $1.1 billion sale of its surgical business to Boston Scientific, following its acquisition by Baring Private Equity Asia. Lumenis will continue operating its medical aesthetics and ophthalmology divisions. The company has undergone ownership handovers and is preparing for the possible sale of additional activities. The surgical division being sold is the most profitable, contributing to the companys annual profit of $70-80 million. The funds from the sale are expected to go to Baring Private Equity Asia. Lumenis has a history of financial difficulties but has recovered under Ozer-Armons leadership through cost-cutting, restructuring, and investment in R&D.
AcquisitionInvestment
growth-positive
Boston Scientific to buy Lumenis surgical division for $1.1b
Boston Scientific has announced its plans to acquire the global surgical business of Israeli medical laser company Lumenis from Baring Private Equity Asia (BPEA) for $1.07 billion. The deal is expected to be completed in the second half of 2021. Boston Scientific plans to expand the Yokneam offices into a world center for laser surgery. BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. The acquisition will expand Boston Scientifics global footprint throughout Europe and Asia.
AcquisitionExpand
growth-positive
Lumenis, Inc. Unveils Its First-ever U.S. Tour With Launch Of LuMobile -- A Mobile Outdoor Tradeshow Booth
Lumenis Inc. is launching its first-ever mobile tour called LuMobile, which will bring its flagship devices to practitioners in a safe environment. The 20-city mobile tour will kick off in Chicago and travel to major cities across the country. The tour was conceived in response to the COVID-19 pandemic, providing physicians and practitioners with in-person experiences with new technologies. The LuMobile will showcase Lumenis newest and most popular technologies, including the Stellar M22 for aesthetics, MOSES 2.0 surgical platform, and Selecta DUET and Optima IPL ophthalmic devices. The mobile tradeshow booth will feature live demos, interactions with Lumenis representatives, and red carpet events. The goal is to advance education, patient care, and new breakthroughs in medical technology. The mobile tour creates a safe environment for professionals to learn about and experience Lumenis innovations.
CustomersPartners
growth-positive
Lumenis Announces NuEra® Tight with FocalRF™ Technology, a Breakthrough in Aesthetic Medical Devices, now available in Europe and the Middle East offering Personalized Body Sculpting Treatments
Lumenis Ltd., the worlds largest energy-based medical device company, has announced the availability of its revolutionary NuEra Tight with FocalRF technology in Europe and the Middle East. The device offers personalized solutions for fat reduction, skin tightening, cellulite, and wrinkle reduction. The new technology allows for tailored body sculpting treatments based on a patients specific needs. The system features advanced tools for aesthetic patients, targeting various skin and tissue conditions. The easy-to-use interface ensures therapeutic temperature throughout the procedure, and the device can be used for the entire range of body sculpting treatments. Lumenis is a global leader in minimally-invasive clinical solutions and has successfully developed innovative energy-based technologies. The company is a portfolio company of Baring Private Equity Asia.
CustomersPartners
growth-positive
Israeli MedTech giant Lumenis launches non-invasive aesthetic treatment
Israeli MedTech company Lumenis has launched its new non-invasive aesthetic body treatment, the NuEra Tight with FocalRF technology. The platform offers personalized modifications for all body types, providing physicians with a non-invasive tool for aesthetic patients. The product is set to launch in the U.S. in August, with launches in Europe, Asia, and the Middle East to follow later this year. Lumenis is a global leader in energy-based medical solutions for aesthetic, surgical, and ophthalmic applications.
Customers
growth-positive
Private Equity Firm Baring Completes $1.2 Billion Lumenis Acquisition
Baring Private Equity Asia Ltd. has completed the acquisition of Lumenis Ltd., an Israel-based medical and aesthetic laser company. The deal was valued at $1.2 billion, and it marks a growth-positive impact on Lumenis. Baring, a Hong Kong-based private equity firm with over $20 billion in assets under management, has a focus on Asia, which is one of Lumenis main markets. Lumenis develops laser-based treatments for various markets. The company was previously listed on Nasdaq and had experienced fluctuations in valuation before being acquired by XIO Group in 2015. The acquisition by Baring was made possible after all regulators, including the Chinese regulator, approved the deal.
Acquisition
growth-positive
Lumenis Launches the New LightSheer QUATTRO, Laser Hair Removal Platform, at 22nd International Master Course on Aging Science (IMCAS)
Lumenis Ltd. announces the launch of its newest platform, the LightSheer Quattro, positioning it ahead of the market in the diode laser hair removal industry. The system offers laser hair removal treatments for all skin types and treatment of pigmented and vascular lesions. The LightSheer Quattro combines High Speed Vacuum assisted technology with ChillTip™ Integrated Contact cooling technology for comfortable and effective treatments. Lumenis will showcase the LightSheer Quattro and other systems at the IMCAS conference. The company is a global leader in minimally-invasive clinical solutions and is a portfolio company of XIO Group.
Customers
growth-negative
Major layoffs at Lumenis ahead of sale
Israeli medical esthetics and surgical company Lumenis has begun layoffs and restructuring ahead of the companys sale to Baring Private Equity Asia. The company has canceled two esthetics projects that were in the development stage. Lumenis controlling shareholder XIO Group announced its intention to sell the company to BPEA at a company valuation of over $1 billion. Lumenis develops and markets light energy-based devices for medical treatment. BPEA, a private equity fund, focuses on Asia and has made acquisitions totaling over $12 billion. Lumenis revenue totaled $400 million in 2018.
Layoffs
growth-positive
Baring Private Equity Signs MoU for $1.2 Billion Lumenis Acquisition Deal
Private equity firm Baring Private Equity Asia Ltd. has signed a memorandum of understanding for the acquisition of Lumenis Ltd. for $1.2 billion. The deal is expected to close in early 2020. Lumenis, an Israel-based medical and aesthetic laser company, was previously owned by XIO Group. Baring has already performed due diligence, and completion of the deal depends on regulatory approval and XIO settling its legal disagreements.
Acquisition
growth-positive
Baring Private Equity Asia Nearing Acquisition of Medical Laser Company Lumenis, Report Says
Private equity firm Baring Private Equity Asia Ltd. is nearing the acquisition of Lumenis Ltd., an Israel-based medical and aesthetic laser company. The firm is in exclusive talks with Lumenis owner XIO Group. The deal could see Lumenis valued above $1 billion. Lumenis develops laser-based treatments for surgical, ophthalmological, and aesthetic markets. A previous deal with British private equity firm CVC Capital Partners, valued at just under $1 billion, failed to materialize.
Acquisition
growth-positive
Lumenis Introduces a New Skin Rejuvenating Technology, Legend Pro+™, at the 17th Aesthetic & Anti-Aging Medicine World Congress
Lumenis Ltd. has launched its newest platform, the Legend Pro+, at the 17th Aesthetic & Anti-Aging Medicine World Congress. The Legend Pro+ is a face and body platform that offers a comfortable solution with immediate results and minimal pain and downtime. It combines four innovative technologies based on RF current to provide a complete toolkit for tailor-made sessions. The platform can treat the skin from within, toning the muscles of the face and body. Lumenis is excited to introduce the Legend Pro+ and believes in the clinical benefits of its unique RF technologies. The company will also be showcasing other products at the conference.
CustomersPartners
growth-negative
Lumenis $1b sale to CVC still on hold
Israeli medical device company Lumenis, which develops and markets medical devices based on laser treatment, remains under the ownership of XIO Group despite reports of a potential sale to CVC Capital Partners. The deal has not moved forward, and Lumenis is still fully owned by XIO Group. The company has three divisions: esthetic treatment, ophthalmologic laser surgery, and other laser surgery. Lumenis had $400 million in revenue and its products are marketed worldwide. The company was acquired by XIO Group in 2015 for $520 million. Lumenis encountered difficulties in the past but improved under new management. The article was published on March 31, 2019.
Acquisition
growth-positive
Lumenis Announces New Clinical Breakthroughs Using Its Patent-Protected MOSES™ Technology
Lumenis Ltd., a leading energy-based medical device company, has announced new clinical evidence and advantages in lithotripsy and benign prostatic hyperplasia (BPH) treatments using its MOSES Technology. The technology, which was released two years ago, uses a combination of holmium lasers and fibers to optimize energy transmission. Clinical evidence has shown that lithotripsy procedures conducted with MOSES result in faster and more efficient procedures with a significant reduction in stone retropulsion. The technology is being researched by leading academic institutions worldwide.
CustomersExpand
growth-positive
Lumenis marks Women's Day with 'No more stretch marks' campaign - Exchange4media
Motorola is seeking to disrupt the smartphone market and raise its profile among a new generation of consumers with the launch of the Motorola Razr 40 ultra and Razr 40. The company has announced Kriti Sanon as its new brand ambassador and is increasing its advertising across retail channels and D2C sales through its own websites. Motorola is also shifting from a largely digital advertising strategy to mainstream channels. The company is focusing on India, which is becoming the largest consumer market in the world, and is planning to double its volumes over the next three years.
CustomersManagement ChangesExpand
growth-positive
Lumenis Unveils a Wide Range of Innovative Technologies for Multiple Skin and Body Applications at the 2019 American Academy of Dermatology (AAD) Conference
Lumenis Ltd., a global leader in energy-based medical devices, will unveil new solutions at the 2019 American Academy of Dermatology (AAD) Conference. The company will showcase updates to technologies such as LightSheer QUATTRO, SPLENDOR X, and PiQo4. The highlight of the event will be the unveiling of the NuEra Tight, a non-invasive RF technology for skin laxity and cellulite treatment. Lumenis aims to provide safe and effective treatments for various conditions. Esteemed physicians will also present live demonstrations of Lumenis products. The company is committed to continuous innovation and aims to shape the aesthetic market. Lumenis is a portfolio company of XIO Group.
CustomersPartners
growth-positive
CVC set to buy Israeli medical device co Lumenis for $1b
Private equity fund XIO is set to sell Israeli aesthetics medical device and equipment company Lumenis to the UKs CVC Fund for close to $1 billion. XIO Group acquired Yokneam-based Lumenis in 2015 for $520 million. Lumenis develops, manufactures and markets equipment based on light energy, including lasers, for surgical, ophthalmology and aesthetic applications. The company has annual revenue of about $400 million.
AcquisitionAcquired-by
growth-positive
Lumenis Introduces New Laser Hair Removal Solution, SPLENDOR X, at the 2018 American Society of Dermatological Surgery (ASDS)
Lumenis Ltd. announces the launch of SPLENDOR X, a solid state laser system equipped with BLEND X technology for hair removal and skin solutions. The technology will be showcased at the 2018 American Society of Dermatological Surgery. SPLENDOR X offers a wide range of hair removal procedures with adjustable proportions and rapid coverage rate. It is designed to fit treatment requirements for all skin types and hair types. Lumenis will also showcase other products at the event, including NuEra tight and GeneO+. Lumenis is a global leader in energy-based medical devices and is a portfolio company of XIO Group.
Customers
growth-positive
'Moses,' a new stone-striking method, seen as 'game changer' for urologists
Israel-based medical devices firm Lumenis has developed a new technology called Moses, which is said to be even more effective than its original urology lasers. The Moses technology aims to help urologists perform endourology procedures faster and more efficiently, saving time and money. The technology has been patented in the US and is currently being sold globally. Lumenis is also conducting clinical trials to explore the use of the technology in treating enlarged prostate, transitional cell carcinoma, and other tumors in the urinary system. In 2015, Lumenis was acquired by XIO Group for $510 million, and there are reports that US private equity firm CVC Capital Partners is in talks to buy Lumenis for $800 to $900 million.
CustomersPartners
growth-positive
Lumenis organises workshop for mastering laser treatments in aesthetics
The Indian Bio & Health Sciences Industry awards, known as the BioSpectrum Excellence Awards, were recently given away at the Annual Gala Awards Nite on June 30, 2023. The awards honor the achievements of industry leaders in the Indian Bio & Health Sciences Industry. The event is highly anticipated in the industry and has been taking place since 2003.
None
growth-negative
CVC in Talks to Buy Medical Laser Company Lumenis
Private equity firm CVC Capital Partners is in advanced negotiations to acquire Lumenis Ltd., an Israel-based medical and aesthetic laser company, for $800 million to $900 million. The current owner, XIO Group, had acquired Lumenis in 2015 for $510 million. CVC was the highest bidder but has not met the $1 billion asking price set by XIO Group. Lumenis CEO Tzipi Ozer-Armon expressed interest in keeping the companys operations in Israel but cited challenges in the local business environment and a talent crunch. The date of the event described in the article is not provided.
Acquisition
growth-positive
During Endometriosis Awareness Month, Lumenis Marks Exciting Study Outcomes for its Breakthrough Surgical Intervention
Lumenis Ltd., the worlds largest energy-based medical device company, has announced the publication of new clinical evidence for its surgical intervention for endometriosis. The company aims to raise awareness and provide innovative treatment options for women with this disease. Lumenis offers the FiberLase, a high power CO2 laser fiber, which allows surgeons to perform minimally-invasive procedures to treat endometriosis while preserving fertility. The company is proud to fund endometriosis research and support global awareness and educational efforts. Lumenis is committed to advancing technology and empowering women with knowledge about endometriosis and its treatment options.
Customers
growth-positive
Lumenis to launch tattoo removal solution PiQo4 in India - ET HealthWorld
Lumenis Ltd, an energy-based medical devices company, plans to launch PiQo4, a laser technology for multicolor tattoo removal and skin pigmentation treatment. The PiQo4 uses 4 different wavelengths to effectively remove popular ink colors on various skin types. It offers faster treatments and shorter sessions compared to other laser systems. Lumenis India will launch PiQo4 later this year. The company aims to increase awareness of laser technologies through marketing initiatives and education programs. The demand for laser technologies is increasing in various medical specialties in India. The affordability of laser procedures and low insurance coverage in India are challenges in the adoption of laser technologies.
Customers
growth-positive
New Solution for Delicate and Precise Middle Ear Surgery
Lumenis has developed the OtoLase Middle Ear Surgery system, a laser otology system that allows for smooth, individualized, and cost-effective treatment of pathologies in the middle ear. The system uses Lumenis AcuPulse CO2 DUO laser system and offers microsurgical precision during various procedures. The company aims to provide innovative tools to improve surgical performance and enhance patient care. The system has been engineered for safety and ease of use, with features such as an air flow system to eliminate laser plume and a low profile design for reaching small recesses within the middle ear. The technology has been well-received by surgeons.
Partners
growth-positive
Lumenis buys Israeli medical aesthetic co Pollogen
Israeli medical device company Lumenis Ltd. has completed the acquisition of Pollogen Ltd., a medical aesthetic company. The financial details of the deal were not disclosed. The acquisition will strengthen Lumenis position in the beauty segment, particularly in the radio-frequency technology. Lumenis CEO Tzipi Ozer-Armon stated that the addition of Pollogens extensive portfolio will allow them to provide tailored and innovative beauty solutions to their customers. In June, Lumenis was acquired by Chinas XIO Group for $510 million.
Acquisition
growth-positive
China's XIO completes $510m acquisition of Lumenis
Chinese private equity fund XIO has completed the acquisition of Israeli surgical, ophthalmology, and aesthetic applications company Lumenis Ltd. for $510 million. Lumenis shareholders received a 16% premium on the Nasdaq share price. The completion of the deal resulted in Lumenis being delisted from Nasdaq. The company received a $100 million loan from Mizrahi Tefahot Bank and had $105 million in cash at the end of the first quarter. Lumenis is one of the leading companies in Israels aesthetic medical market. The acquisition has brought handsome returns for the companys owners.
Acquisition
N/A
After 2014 IPO and recent takeover rumor, medical laser player Lumenis to be acquired for $510M
The article discusses the terms of use and privacy policy of Questex LLC.
growth-positive
China's XIO Group acquires Lumenis for $510m
Chinese investment fund XIO Group is acquiring Lumenis Ltd. for $510 million, a 16% premium on the share price. The acquisition is seen as a strong recognition and vote of confidence in Lumenis achievements and its employees. Lumenis has transformed into a strong, growing, and profitable company over the past 3 years, with a focus on new products and tripled EBITDA. The two largest shareholders of Lumenis, Viola Group and XT Hi-Tech Investments (1992) Ltd., have entered into a voting agreement with XIO Group. The transaction was advised by Goldman Sachs and Morgan Stanley.
Acquisition
growth-negative
Fosun Pharma eyes Lumenis
Chinese company Fosun Pharma, which previously acquired Alma Lasers, is interested in acquiring Lumenis Ltd., a competitor in aesthetic medicine. Fosuns interest is in the preliminary stages and has not yet reached negotiations. However, since the matter has become public, Fosun may withdraw due to the impact on share price and trust between the parties. Lumenis is a well-run company with a broad product offering, and its revenue and profit have been growing. Lumenis full-year guidance shows further growth. The article was published on February 17, 2015.
Acquisition
Lumenis Team
Employee Info
| Employees (range) | 500+ |
| Exact count | 1428 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Lumenis Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 93/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 520042557 |
| Crunchbase | lumenis |
| Phone | +97249599000 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-09-02T00:00:00.000Z |
| Created | 2014-08-04T00:00:00.000Z |
| Status detail | Acquired by XIO on Jun, 2015 |